Contact
searchSearch
HMP Global
Login

News

News
Initiation of Bispecific Antibodies Associated With High Care Costs for Patients With MM
08/24/2026
Rebecca Amrick
A study found that longer hospitalizations were associated with higher care costs among patients with MM initiating treatment with bispecific antibodies, raising concerns about care delivery and access.
A study found that longer hospitalizations were associated with higher care costs among patients with MM initiating treatment with bispecific antibodies, raising concerns about care delivery and access.
A study found that longer...
08/24/2026
Journal of Clinical Pathways
News
Cytopenia Associated With Worse Survival Outcomes in Patients With Myelofibrosis
08/17/2026
Rebecca Amrick
A study found that the presence of cytopenia was associated with poor survival outcomes in patients with myelofibrosis, suggesting cytopenia as a prognostic marker to monitor during disease management.
A study found that the presence of cytopenia was associated with poor survival outcomes in patients with myelofibrosis, suggesting cytopenia as a prognostic marker to monitor during disease management.
A study found that the presence...
08/17/2026
Journal of Clinical Pathways
News
The Impact of Interventions on Serious Illness Conversations
08/14/2026
Rebecca Amrick
Researchers found that intervention strategies focused on clinician reminders could increase rates of serious illness conversations among patients with projected poor health outcomes.
Researchers found that intervention strategies focused on clinician reminders could increase rates of serious illness conversations among patients with projected poor health outcomes.
Researchers found that...
08/14/2026
Journal of Clinical Pathways
News
The Current Treatment Landscape for Myelofibrosis
08/10/2026
Rebecca Amrick
Researchers provided a comprehensive overview of the main treatment options for myelofibrosis (MF), including the primary Janus kinase (JAK) inhibitors, potential combination strategies, and non-pharmacologic interventions used in disease...
Researchers provided a comprehensive overview of the main treatment options for myelofibrosis (MF), including the primary Janus kinase (JAK) inhibitors, potential combination strategies, and non-pharmacologic interventions used in disease...
Researchers provided a...
08/10/2026
Journal of Clinical Pathways
News
The Efficacy and Safety of Teclistamab Among Patients With Relapsed or Refractory MM
08/07/2026
Rebecca Amrick
Researchers found that teclistamab was associated with better survival outcomes but increased rates of infection among patients with relapsed and refractory multiple myeloma (RRMM), showcasing how therapies could create a choice between...
Researchers found that teclistamab was associated with better survival outcomes but increased rates of infection among patients with relapsed and refractory multiple myeloma (RRMM), showcasing how therapies could create a choice between...
Researchers found that...
08/07/2026
Journal of Clinical Pathways
News
Financial Navigation Not Associated With Reduced Financial Hardship
08/03/2026
Rebecca Amrick
A study found no association between financial navigation and improvements in financial hardship or quality of life among patients with cancer, highlighting the need for future research on strategies that could reduce cancer-related financial...
A study found no association between financial navigation and improvements in financial hardship or quality of life among patients with cancer, highlighting the need for future research on strategies that could reduce cancer-related financial...
A study found no association...
08/03/2026
Journal of Clinical Pathways
News
High-Risk Features Impact Patient Survival in Relapsed or Refractory MM
07/27/2026
Rebecca Amrick
A study found that high-risk features such as extramedullary disease, plasma cell leukemia, and focal lesions were associated with poor survival outcomes among patients with relapsed or refractory multiple myeloma (MM).
A study found that high-risk features such as extramedullary disease, plasma cell leukemia, and focal lesions were associated with poor survival outcomes among patients with relapsed or refractory multiple myeloma (MM).
A study found that high-risk...
07/27/2026
Journal of Clinical Pathways
News
Medicare’s Oncology Care Model Demonstrated Modest Payment Reductions for Patients Receiving Chemotherapy
07/24/2026
Rebecca Amrick
A study found that Medicare’s Oncology Care Model resulted in modest payment reductions but had little impact on care utilization or quality for patients undergoing chemotherapy.
A study found that Medicare’s Oncology Care Model resulted in modest payment reductions but had little impact on care utilization or quality for patients undergoing chemotherapy.
A study found that Medicare’s...
07/24/2026
Journal of Clinical Pathways
News
Selinexor Plus Ruxolitinib Demonstrates Improved Efficacy in Patients With Myelofibrosis
07/22/2026
Rebecca Amrick
Selinexor plus ruxolitinib showed improved effectiveness and consistent safety than ruxolitinib alone among patients with myelofibrosis, indicating it could be a promising first-line treatment option.
Selinexor plus ruxolitinib showed improved effectiveness and consistent safety than ruxolitinib alone among patients with myelofibrosis, indicating it could be a promising first-line treatment option.
Selinexor plus ruxolitinib...
07/22/2026
Journal of Clinical Pathways
News
Patients With Functional High-Risk MM Could Benefit from Early Receipt of T-Cell Therapy
07/21/2026
Rebecca Amrick
A study found that defining functional high-risk multiple myeloma (MM) disease progression within 36 months may better identify patients who could benefit from earlier T-cell therapy, potentially improving survival outcomes.
A study found that defining functional high-risk multiple myeloma (MM) disease progression within 36 months may better identify patients who could benefit from earlier T-cell therapy, potentially improving survival outcomes.
A study found that defining...
07/21/2026
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use